Cd33 Positive Microglia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CD33 (Siglec-3) is a sialic acid-binding immunoglobulin-like lectin expressed on microglia and other myeloid cells. CD33-positive microglia play a complex role in neurodegenerative diseases, particularly Alzheimer's disease, where genetic variants in CD33 have been associated with altered disease risk. [@expression]
Overview
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions. [@targeting]
Cd33 Positive Microglia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CD33 (Siglec-3) is a sialic acid-binding immunoglobulin-like lectin expressed on microglia and other myeloid cells. CD33-positive microglia play a complex role in neurodegenerative diseases, particularly Alzheimer's disease, where genetic variants in CD33 have been associated with altered disease risk. [@expression]
Overview
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions. [@targeting]
Cytokine Production: Modulates production of pro-inflammatory cytokines
Immune Activation: Regulates microglial activation states
Therapeutic Targeting
CD33-Targeting Strategies
Anti-CD33 Antibodies: Immunotherapy approaches to modulate microglial function
Small Molecule Inhibitors: Compounds targeting CD33 signaling pathways
Gene Silencing: siRNA and antisense approaches
Clinical Relevance
CD33 risk variants influence treatment response
CD33 expression serves as a biomarker
Targeting CD33 may enhance microglial clearance functions
Research Findings
Human Studies
Increased CD33 expression in AD brain tissue
Association between CD33 variants and disease progression
Correlation with amyloid burden in specific brain regions
Animal Models
CD33 knockout mice show altered amyloid pathology
Deficiency leads to enhanced microglial phagocytosis
Modulates neuroinflammatory responses
Background
The study of Cd33 Positive Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.